AstraZeneca and Daiichi Sankyo's HER2-directed antibody-drug conjugate Enhertu (trastuzumab deruxtecan) already has ...

The US company also sells a small-molecule HER2 inhibitor – Tukysa (tucatinib) – which is now partnered with Merck & Co outside the US, Canada and Europe as part of a $4.2 billion alliance ...

Relay Therapeutics' financial stability is strong, but zero Q3 2024 revenue and rising net losses raise concerns. Find out ...

Given the success of the previous Research Topic 'Exploring Small Molecule Inhibitors in Cardiovascular and Cerebrovascular Diseases', we are pleased to ...

The Food and Drug Administration (FDA) has granted Priority Review to the New Drug Application for zongertinib for the treatment of adult patients with ...

BAY 2927088 is an oral small-molecule tyrosine kinase inhibitor designed to selectively target mutant HER2, including HER2 exon 20 insertions and point mutations, as well as EGFR while maintaining ...

As part of Arvinas global collaboration with Pfizer, the companies plan to: Announce topline data for the VERITAC-2 Phase 3 monotherapy cli ...